Cell/Gene Tx channel feed

'Find a way, or make one': How two sci­en­tists hope to re­vi­tal­ize CRISPR's rare dis­ease cri­sis

3 days ago
R&D
In Focus

CRISPR Ther­a­peu­tic­s' gene edit­ing ther­a­py re­duces bad cho­les­terol and triglyc­erides by as much as 80%

4 days ago
R&D

Sin­ga­pore car­dio gene ther­a­py biotech col­lects $45M as it plots Eu­rope ex­pan­sion

6 days ago
Financing
Startups

FDA ad­comm will re­view Capri­cor's cell ther­a­py for Duchenne mus­cu­lar dy­s­tro­phy

6 days ago
Pharma
FDA+

J&J's eye dis­ease gene ther­a­py bo­ta-vec fails in Phase 3 tri­al

6 days ago
R&D

Ear­ly bits of in vi­vo CAR-T hu­man da­ta emerge from biotech tri­als in Chi­na

6 days ago
R&D
China

Ex­clu­sive: Ver­tex drops AAV gene ther­a­py re­search, tR­NA ther­a­py part­ner­ship

Last week
R&D

Feng Zhang’s pro­tein nanopar­ti­cle start­up Aera Ther­a­peu­tics turns to lipid nanopar­ti­cles to jump­start its pipeline

Last week
R&D

Bris­tol My­ers to close cell ther­a­py site in Illi­nois as part of on­go­ing cost cuts

Last week
People
Manufacturing

FDA ap­proves Abeona’s skin dis­ease cell ther­a­py

Last week
Pharma
FDA+

RFK Jr. touts CMS pro­gram test­ing new ways to pay for sick­le cell dis­ease treat­ment

3 weeks ago
Pharma

Cari­bou lays off 32% of staff, cuts lu­pus cell ther­a­py pro­gram be­fore first pa­tient

3 weeks ago
People
R&D

Ayr­mid miss­es dead­line for de­tailed of­fer to top pri­vate eq­ui­ty bid for blue­bird

4 weeks ago
Deals

Sid­dhartha Mukher­jee’s cell ther­a­py start­up nar­rows fo­cus as staff shrinks

4 weeks ago
R&D

Verve un­veils ear­ly da­ta from sec­ond at­tempt at heart dis­ease gene edit­ing

4 weeks ago
R&D

Carte­sian re­veals long-term mid-stage da­ta for cell ther­a­py in myas­the­nia gravis

Last month
R&D

Cell and gene ther­a­py CD­MO Am­pli­fy­Bio shuts down over 's­carci­ty' of fund­ing

Last month
Manufacturing

Ex­clu­sive: Neu­rona bags $102M to treat epilep­sy with cell ther­a­py

Last month
Financing
Startups

FDA cuts stir buy­er’s re­morse for some bio­phar­ma lead­ers, once ex­cit­ed by Trump

Last month
Pharma
FDA+

At­se­na gets Bain's sup­port in $150M Se­ries C to thwart blind­ness with gene ther­a­py

Last month
Financing
Startups

New CD­MO emerges, ac­quires cell and gene man­u­fac­tur­er Land­mark Bio

Last month
Deals
Manufacturing

DC court sides with HHS in Ver­tex's fer­til­i­ty pro­gram fight

Last month
Pharma
Law

Tenaya to lay off about one-third of staff, re­veals heart gene ther­a­py da­ta

Last month
R&D

Ver­tex’s sec­ond-gen­er­a­tion di­a­betes cell ther­a­py fails ear­ly-stage study

Last month
R&D
1234 Next page Last page
A service from the Financial Times